An Open label, balanced, randomized, multicentre, multiple-dose, two-period, two-treatment, two-sequence, steady state, crossover comparativebioequivalence study of two formulations of Azathioprine in adultpatients with Rheumatoid Arthritis (RA)

Orion Pharma0 个研究点目标入组 40 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 1 期
状态: 已完成
发起方: Orion Pharma
入组人数: 40

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Ba/be

入排标准

入选标准

•1.Adult patients, aged between 18 and 55 years (both inclusive) with acceptable BMI
•2.RA patients on maintenance therapy with twice daily 50 mg oral Azathioprine with or without a fixed dose (maximum of 30 mg/week) of Methotrexate.
•Having moderate to aggressive disease stage, as per American Rheumatism Association defined by the presence of at least 3 of the following criteria:
•(a) tenderness of more than 6 joints
•(b) swelling of more than 3 joints
•(c) morning stiffness longer than 45 minutes
•(d) articular index greater than 20
•(e) ESR greater than 28 mm/h.
•3.As per discretion of Principal Investigator, CRP, ANTI-CCP antibodies
•& RA factor done within 6 months of screening or at screening
•suggestive of active Rheumatoid arthritis
•4.Is subject off corticosteroids or on a stable dose of corticosteroid for at least 2 weeks prior to enrollment. The maximal daily dose of corticosteroid at Baseline must not exceed the equivalent of 10 mg of prednisone.
•5.Is subject free of any clinically significant condition or situation, other than RA that, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study.
•6.Are the Liver and kidney function (ALT /AST/ AP / creatinine < 2 x upper normal limit).
•7.Are the Subject?s Screening and Baseline clinical laboratory tests (complete blood count [CBC] and blood chemistries) within acceptable ranges.
•8.Subjects are willing and able to adhere to the study visit schedule and other protocol requirements as evidenced by a written informed consent.
•9.If the subject is a woman of child-bearing potential or a man, is he/she agreeing to use a medically accepted method of contraception prior to screening, while receiving protocol-specified medication, and for 6 months after stopping the medication.
•10.For female subjects of childbearing potential is serum pregnancy test (beta-HCG) negative.

排除标准

•1.Is the subject on therapy with any other agent apart from twice daily dose of Azathioprine alone or alongwith use of NSAIDs, fixed low-dose glucocorticoids and/or fixed dose of Methotrexate Anemia (hemoglobin < 08 gm %).
•2.Does the subject have Anemia (hemoglobin < 08 gm %).
•3. Does the patient have with low or absent TPMT activity (<5.5 unit)
•4. Does the patient have bone marrow suppression (platelets / leucocytes < 1 x lower normal level).
•5.Did the patient have any small bowel surgery interfering significantly with resorptive area.
•6.Is subject concomitantly using allopurinol, ACE-inhibitors or furosemide.
•7.Is the patient pregnanct or expecting pregnancy or lactation within 6 months.
•8.Does the subject have a history of a known allergy/sensitivity to study drug or its excipients
•9.Did subject have serious infections (eg, active hepatitis, pneumonia, or pyelonephritis) within 2 months of screening. (Less serious infections (such as acute upper respiratory tract infection [colds] or a simple urinary tract infection) need not be considered as an exclusion at the discretion of the investigator)
•10.Did subjects have a nontuberculous mycobacterial infection or opportunistic infection (eg, cytomegalovirus, Pneumocystis carinii, aspergillosis) within 6 months prior to Screening
•11.Subjects who have a known infection with human immunodeficiency virus (HIV) and/or hepatitis B or hepatitis C
•12.Does the subject have current signs and symptoms of systemic lupus erythematosus, or severe, progressive, or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic, or cerebral diseases.
•13.Does the subject have a known history of demyelinating disease suggestive of multiple sclerosis or optic neuritis.
•14.Does the subject have presence of a transplanted organ (with the exception of a corneal transplant >3 months prior to screening).
•15.Does the subject have a history of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (eg, nodes in the posterior triangle of the neck, infra-clavicular, epitrochlear, or periaortic areas), or splenomegaly.
•16.Does the subject have any current known malignancy or malignancy within 5 years prior to screening (except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence).
•17.Does the subject have poor tolerability of venipuncture or lack of adequate venous access for required blood sampling during the study period.
•18.Does the subject have a known substance abuse or dependency (drug or alcohol) within 3 years of Screening
•19.Does the subject have other inflammatory diseases that might interfere with the evaluation of the Rheumatoid Arthritis.
•20.Does the subject have a history of latent or active granulomatous infection, including TB, histoplasmosis, or coccidioidomycosis, prior to Screening.
•21.Has the subject received any specified prohibited treatment more recently than the indicated washout period prior to Screening
•22.Is the subject participating in any other clinical study or has received treatment with any investigational drug or device within 3 months prior Screening
•23.Is the subject part of the staff or a family member of the staff personnel directly involved with this study.
•24.Does the subject have any other condition that, in the investigator?s judgment, might i

研究者

发起方

Orion Pharma

相似试验

进行中（未招募）

不适用

Bioequivalence study of Azathioprine to measure the pharmacokinetic profiles, safety and tolerability of Test product when compared to the reference product.

CTRI/2014/11/005175Alkem Laboratories Ltd40

进行中（未招募）

不适用

A bio-equivalence study to characterize the rate and extent of absorption of Melphalan after oraladministration and to assess the bioequivalence of the sponsorâ??s test productMelphalan Tablets 2 mg relative to that of the reference product ALKERANÂ®(melphalan) Tablets 2 mg in adult patients

CTRI/2013/12/004205Alvogen Pine Brook Inc60

进行中（未招募）

不适用

A study of Capecitabine 200 mg/ ml with Xeloda 500 mg (Capecitabine) at a dose of 2000 mg in adult human cancer patients under fed conditions.

CTRI/2020/10/028417Shilpa Medicare Limited

进行中（未招募）

Unknown

euprolide acetate in the treatment of Prostate Cancer.

CTRI/2023/09/057619Pharmathen S.A.

已完成

不适用

Imatinib Mesylate Oral Solution 400mg/5ml with GleevecÂ® (Imatinib mesylate) Tablets 400mg in adult human subjects with Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumors under fed condition.

CTRI/2020/03/024404Shilpa Medicare Limited35